

Maja Jazvinščak Jembrek^{1,2*},
Mirjana Babić^{2,3},
Nela Pivac⁴,
Patrick R. Hof⁵,
Goran Šimić³

¹Laboratory for Molecular Neuropharmacology,
Division of Molecular Medicine, Ruđer Bošković
Institute, Zagreb, Croatia

²Croatian Catholic University, Department of
Psychology, Zagreb, Croatia

³Department for Neuroscience, Croatian Institute
for Brain Research, University of Zagreb Medical
School, Zagreb, Croatia

⁴Laboratory for Molecular Psychiatry, Division
of Molecular Medicine, Ruđer Bošković Institute,
Zagreb, Croatia

⁵Fishberg Department of Neuroscience and
Friedman Brain Institute, Icahn School of Medicine
at Mount Sinai, New York, NY 10029, USA

Received 21 November 2013
accepted 25 November 2013

HYPERPHOSPHORYLATION OF TAU BY GSK-3 β IN ALZHEIMER'S DISEASE: THE INTERACTION OF A β AND SPHINGOLIPID MEDIATORS AS A THERAPEUTIC TARGET

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the extracellular deposits of β amyloid peptides (A β) in senile plaques, and intracellular aggregates of hyperphosphorylated tau in neurofibrillary tangles (NFT). Although accumulation of A β has been long considered a leading hypothesis in the disease pathology, it is increasingly evident that the role hyperphosphorylation of tau in destabilization of microtubule assembly and disturbance of axonal transport is equally detrimental in the neurodegenerative process. The main kinase involved in phosphorylation of tau is glycogen-synthase kinase 3-beta (GSK-3 β). Intracellular accumulation of A β also likely induces increase in hyperphosphorylated tau by a mechanism dependent on GSK-3 β . In addition, A β affects production of ceramides, the major sphingolipids in mammalian cells, by acting on sphingomyelinases, enzymes responsible for the catabolic formation of ceramides from the sphingomyelin. Generated ceramides in turn increase production of A β by acting on β -secretase, a key enzyme in the proteolytic processing of the amyloid precursor protein (APP), altogether leading to a ceramide-A β -hyperphosphorylated tau cascade that ends in neuronal death. Modulators and inhibitors acting on members of this devastating cascade are considered as potential targets for AD therapy. There is still no adequate treatment for AD patients. Novel therapeutic strategies increasingly consider the combination of multiple targets and interactions among the key members of implicated molecular pathways. This review summarizes recent findings and therapeutic perspectives in the pathology and treatment of AD, with the emphasis on the interplay between hyperphosphorylated tau, amyloid β , and sphingolipid mediators.

Keywords

• Alzheimer's disease • Tau hyperphosphorylation • Glycogen-synthase kinase 3 β • Amyloid β • Sphingolipids

© Versita Sp. z o.o.

Abbreviations

A β	- Amyloid β protein
AD	- Alzheimer's disease
AICD	- APP intracellular domain
APP	- Amyloid precursor protein
BACE1	- β -secretase
BDNF	- Brain-derived neurotrophic factor
Cer	- Ceramides
Cdk5	- Cyclin-dependent kinase 5
GSK-3 β	- Glycogen synthase kinase-3 β
NFT	- Neurofibrillary tangles
PA	- Palmitic acid
PHF	- Paired helical filaments
PI3-K	- Phosphatidylinositol 3-kinase
PP2A	- Protein phosphatase 2A
NFT	- Neurofibrillary tangles
SM	- Sphingomyelinase
SPT	- Serine palmitoyltransferase

A link between hyperphosphorylated tau, A β , and lipids

Alzheimer's disease (AD) is a chronic progressive neurodegenerative disorder and the leading cause of dementia syndrome in elderly people. Existing treatments for AD do not delay or modify progression of the disease, and the number of affected people is estimated to rise to 100 million worldwide by 2050 without new effective therapy [1]. Besides age that is considered the most significant risk factor for AD, epidemiological studies indicate that a high-fat diet might contribute to its development, the degree of saturation of fatty acid being the most important factor determining risk [2,3]. In fact, white matter from AD brain is characterized by increased fatty acid content, although the cholesterol

levels are decreased in comparison to healthy subjects [4,5]. Hence, understanding the etiopathological processes of AD, particularly in respect of lipid contributions, is of major importance for the development of novel therapeutic strategies that will reverse or slow down progression of the disease.

The most researched neuropathological hallmarks found in AD brains are extracellular senile plaques containing neurotoxic amyloid β -peptide (A β) derived from the amyloid precursor protein (APP), and intracellular aggregates of abnormally phosphorylated tau protein that form paired helical filaments (PHF). They associate and build up densely packed networks of neurofibrillary tangles (NFT) [6-8]. Besides AD, phosphorylation of tau protein is also implicated in the pathogenesis of several related disorders called tauopathies [9,10].

* E-mail: Maja.Jazvinscak.Jembrek@irb.hr

Although formation of insoluble A β fragments in an amyloidogenic pathway by proteolytic cleavage of APP with β - and γ -secretases has been considered a key step in the pathogenesis of AD, tau increasingly emerged as an obligatory member of the neurodegenerative process [1]. Moreover, a number of reports found evidence for a relationship between A β and tau in AD [11-14]. Soluble A β oligomers facilitate wild-type human tau accumulation and hyperphosphorylation, leading to neuritic dystrophy [15], and learning and memory deficits in transgenic mice [16]. In addition, treatments with modulators of γ -secretase can reverse A β -associated tau pathology and reduce hyperphosphorylated tau levels in AD mouse models [17,18]. Interactions between tau and lipids also seem important in AD pathology. Phosphorylated tau was found in specific microdomains of plasma membrane called lipid rafts in neuronal cells exposed to A β peptides [19], in lipid rafts of an AD mouse model, and in lipid rafts from AD brain [20]. Evidence indicates connections between lipids and A β as well. While proteolytic processing of APP is influenced by the lipid composition of cellular membranes, particularly with cholesterol and sphingolipids, A β in turn plays an essential role in regulating lipid homeostasis [21].

Tau protein and axonal assembly and stability

Tau, a protein with multiple phosphorylation sites, belongs to the family of microtubule-associated proteins. It is highly expressed in neurons, particularly in axons, with an essential role in the assembly of tubulin monomers into microtubules that are fundamental cellular structures for preservation of neuronal shape and axonal transport [22]. Therefore, tau plays a crucial role in the formation and maintenance of axons, microtubule dynamics, neurite outgrowth, and neuritic stability [23].

Tau is encoded by a single gene, but due to alternative splicing of mRNA, several tau isoforms with differential affinity for microtubules are expressed in human brain in a developmental [24], cell-specific, and pathology-related manner [25,26]. In early

developmental stages only the smallest tau isoform is expressed, while all tau isoforms are expressed during adulthood [27]. These isoforms differ by the presence of either three or four semiconserved repeat-regions in the C-terminus part of the molecule that form highly homologous microtubule-binding domain, and by the presence of two, one, or no inserts in the N-terminus part. Through these microtubule-binding repeats at the C-terminus, tau protein exerts its specific function in microtubule assembly and stabilization [28,29]. At the level of both mRNA and protein, a ratio of tau isoforms with 4 and 3 repeats (4R:3R) is approximately equal in healthy adult brain [30]. Alterations in 4R:3R ratio and mutations in the tau gene that cause amino acid substitutions lead to formation of intracellular inclusions consisting of highly phosphorylated tau with abnormal conformation [1,31].

Hyperphosphorylation of tau leads to toxicity and loss of function

Function of tau is modulated by alterations in its phosphorylation pattern, in principle on various threonine (Thr) and serine (Ser) residues. The longest human isoform has 80 Ser and Thr residues and additional 5 tyrosine residues indicating that almost 20% of the molecule are amino acids that can be phosphorylated [32]. The exact contribution of each phosphorylation sites or subsets of phosphorylation sites for normal tau function is still not completely understood. The normal tau contains 2-3 moles of phosphate per mole of protein, while in AD brain this phosphorylation stoichiometry is three to four times higher, with all isoforms being found in abnormally phosphorylated NFT [33]. By mass spectroscopy and antibody staining, the total number of identified phosphorylated residues in insoluble tau from AD brains is 45, which is significantly higher than the number of phosphorylated residues in soluble tau of healthy controls, and represents more than half of residues available for phosphorylation [1,34,35].

Hyperphosphorylation results in dissociation of tau protein from microtubules and impairs its role in microtubule assembly and stabilization, leading to the loss of the normal content of microtubules [36]. Certain residues,

either within the microtubule-binding domain or apart from it, such as Thr²¹², Ser²¹⁴, Thr²³¹, Ser²³⁵ and Ser²⁶², have been recognized as the major sites contributing to the segregation of tau protein from the microtubules [37-39]. In addition, hyperphosphorylation deregulates axonal transport of vesicles and other cargoes further affecting axonal length and function. This ends in neuronal degeneration, synaptic loss, and ultimately cell death, a key end-point histopathological hallmark of AD [9,30,32,40].

In addition to phosphorylation-dependent loss of function, aberrant phosphorylation of tau induces tau-tau interactions and self-assembly into tangles of paired helical filaments that build up NFT inside neurons [41]. Development of NFT occurs in a stepwise manner, and the specific pattern of tau phosphorylation correlates with severity of neuronal cytopathology [42]. The appearance of pathological changes can be classified in three morphological stages: pre-neurofibrillary tangle, intra-, and extra neuronal fibrillary tangles [43]. NFT also appear in a stereotypical order, certain regions being affected before others [44-48].

Tau can be phosphorylated by proline-directed and non-proline directed kinases [49,50]. *In vitro* and cell studies revealed that tau is a substrate for at least 17 different kinases with considerable overlap of the phosphorylated residues [1,51]. Among them are glycogen synthase kinase-3 β (GSK-3 β), cyclin-dependent kinase 5 (cdk5) and its regulators, non-receptor tyrosine kinases, casein kinase 1 delta, extracellular signal regulated kinase-2 (ERK2), and cyclic AMP-dependent protein kinase [52-57]. Despite much advances in identifying phosphorylation sites *in vitro*, the individual contributions of each kinase to *in vivo* physiology and pathology are still unknown. The considerable overlap of multiple residues phosphorylated by different kinases *in vitro* suggests that the overall pattern of increased tau phosphorylation is more important than phosphorylation of each particular residue. On the contrary, diverse phosphatases remove phosphate groups and dephosphorylated tau. Protein phosphatase 2A (PP2A) seems to be the major tau phosphatase in human brain [58]. Hence,

coordinated action of protein kinases and phosphatases determines the phosphorylation status of tau, suggesting that downregulation of phosphatases in the AD brain could also lead to tau hyperphosphorylation and the prevalence of abnormal, stable tau form with high aggregation potential [59,60].

GSK-3β as a link between hyperphosphorylated tau and Aβ

GSK-3 is a ubiquitous Ser/Thr kinase that modulates many important processes inside the cell. It has two highly homologous isoforms - GSK-3α and GSK-3β. Activation of GSK-3 has been found in a number of neurodegenerative diseases, including AD. Active GSK-3 localizes to pretangle neurons, dystrophic neurites and NFT in AD brains, and temporal and spatial patterns of GSK-3 expression correlate well with the progression of neurodegeneration [61-63]. Altered activity of both GSK-3 isozymes contributes to key neuropathological hallmarks of AD. While GSK-3α participates in APP processing and deposition of Aβ by regulating the activity of γ-secretase [64], the other isoform GSK-3β is considered as the major tau kinase involved in hyperphosphorylation of tau protein [65,66]. As previously explained, GSK-3β-mediated phosphorylation of tau reduces its affinity for microtubules, and also modulates axonal transport [65,67].

GSK-3β recognizes phosphorylated Ser residues, and phosphorylates Ser and Thr residues in the vicinity of previously phosphorylated Ser residues. It requires prior-phosphorylation by cdk5 *in vitro* [68], while evidence for *in vivo* priming is still missing. Studies on transgenic mice also suggested a crucial role of GSK-3β in AD pathogenesis [69], and a role of cdk5 in elevation of tau hyperphosphorylation and NFT formation [70]. Phosphorylation of tau by GSK-3β may promote formation of tangle-like filament morphology in cell-free models [71]. GSK-3β also mediates tau phosphorylation in cultured cell lines [72], while overactivation of GSK-3 in animal model induces tau hyperphosphorylation together with AD-like cognitive effects such as impairment of spatial memory [73]. Most importantly, it was shown that Aβ oligomers enhance tau phosphorylation (Figure 1) and compromise cell survival through

the mechanism mediated by GSK-3β activation [12,14,69], and neurons from tau-knockout mice are resistant to Aβ-induced toxicity [11]. Moreover, it has been reported that GSK-3β facilitate APP processing and generation of Aβ [74]. Interestingly, presenilin 1, a part of γ-secretase, brings tau and GSK-3β in close proximity as both tau and GSK-3β bind to the same region of presenilin 1 [75]. Altogether these observations suggest that GSK-3β plays a central role in the pathological progression of neurodegeneration *in vivo*, and points to its great potential as a target for therapeutic interventions in AD.

Inhibition of tau phosphorylation and pharmacological outcomes

GSK-3β is considered an interesting therapeutic target, because it links senescence, metabolic diseases, inflammation, protein aggregation, and cell death [76,77]. Accordingly, inhibitors of GSK-3β activity have been intensively sought as potential pharmacological agents in AD therapy. Many studies were performed using

lithium, the most widely used mood stabilizer for treating bipolar disorder. However, lithium is a specific inhibitor of neither GSK-3, nor GSK-3β. It acts as a competitive inhibitor of Mg²⁺ and increases inhibitory phosphorylation at Ser⁹ in GSK-3β through the activation of Akt kinase [78]. Briefly, studies on transgenic mice have shown that inhibition of GSK-3β effectively reduces tau pathology, including level of tau phosphorylation, formation of insoluble aggregates, and axonal degeneration, particularly if administration started during early stages of NFT development (Table 1). However, despite the overall reduction in phosphorylated tau, treatment with lithium failed to improve memory impairments in some studies [79-81].

Regarding Aβ pathology, treatments with lithium resulted in contradictory outcomes. While some studies showed reduced Aβ level and reduced plaques formation [74], increased Aβ production [64], as well as unchanged Aβ production have been reported [77,80]. A more recent study on a double transgenic




Figure 1. Schematic representation of the interactions between hyperphosphorylated tau, Aβ, and ceramides. GSK-3β is the main kinase involved in phosphorylation of tau. By a mechanism that is dependent on GSK-3β, intracellular accumulation of Aβ may also contribute to tau hyperphosphorylation. In addition, Aβ affects production of ceramides by acting on sphingomyelinases, enzymes responsible for the catabolic degradation of sphingomyelin. Generated ceramides in turn increase production of Aβ acting on β-secretase, a key enzyme in the proteolytic processing of amyloid precursor protein (APP). BDNF and presenilin may modulate these interactions, particularly via the PI3-K/Akt signaling pathway. PI3-K activates Akt/protein kinase B, while activated Akt in turn phosphorylates GSK-3β and induces its inactivation and reduction in tau phosphorylation.

Table 1. Effects of GSK-3 inhibitors on tau and A β pathology in diverse transgenic mice models.

Mouse line	Age of mice	GSK-3 inhibitor	Dose	Treatment duration	Effects on AD pathology	Ref
Tau ^{vw}	adult	LiCl	Fed with chow 1.7 g/kg + 2.55 g/kg	4 weeks + 2 weeks	↓ of tau protein in sarkosyl-insoluble fractions ↓ phosphorylation and aggregation of mutant tau	[129]
PDAPP	4 weeks	Li ₂ CO ₃	2.4 g/kg chow	7 months	↓ A β levels ↓ A β plaque deposition	[74]
JNPL3	8-11 months	LiCl	0.6 M (10 ml/g)	30 days	↓ level of aggregated tau in the cortex ↓ axonal degeneration if treatment was started at an early stage	[78]
JNPL3	8-11 months	AR-A014418	30 mmol/kg	Twice daily for 1 month	↓ insoluble tau levels in the brain stem	[78]
PrP T44 Ag	2-6 months	LiCl	2.0 g per kg chow	5 months	↓ tau lesions (promotion of ubiquitination) development of more soluble tau aggregates in spinal cord no obvious effect on tau phosphorylation ↓ number of tau-positive spheroids in spinal cord at 9 months	[130]
PrP T44 Ag	5-9 months	LiCl	2.0 g per kg chow	5 months	limited clearance of tau aggregates	[130]
GSK-3/VLW	12 months	LiCl	1.7 g LiCl/kg chow	7.5 months	no signs of phospho-tau accumulation or aggregation	[131]
GSK-3/VLW	18 months	LiCl	Fed with chow 1.7 g/kg + 2.55 g/kg	4 weeks + 2 weeks	incomplete reversal of tau pathology without effect on amyloid-like pathology	[131]
hAPP tg	3 months	LiCl	20 mg/kg	3 months	Improved water maze performance ↓ A β and plaques formation ↓ A β phosphorylation of APP	[132]
3xTg-AD	15 months	LiCl	300 μ l of 0.6 mol/l	4 weeks	↓ tau phosphorylation unchanged A β load without improvement in working memory deficits	[80]
APP ^{sw} -tau ^{vw}	9 or 12 months	NP12	200 mg/kg	3 months	↓ levels of tau phosphorylation ↓ A β deposition ↓ astrocytic proliferation preserved neuronal survival in the entorhinal cortex and CA1 prevention of memory deficits	[81]
Tgtau30	3 months	Li ₂ CO ₃	Chronic chow feeding 2.4 g/kg chow	8 months	no changes in the development of NFT	[133]
Tgtau30	9 months	Li ₂ CO ₃	Oral gavage 350 mg/kg	1 month	↓ tau phosphorylation and sarkosyl-insoluble aggregated tau in CNS ↓ density of NFT without effect on tau ubiquitination ↑ LC3, marker of autophagic vacuoles motor and working memory deficits not rescued	[133]
3xTg-AD	13 months	MMBO	3 and 10 mg/kg	22 days	↓ tau phosphorylation improved cognitive behavioral deficit without changes in A β level and A β plaque formation	[134]
3xTg-AD	13 months	C-7a	20 and 50 mg/kg	Twice daily for 21 days	↓ tau phosphorylation in hippocampus prevention of short-term memory deficit	[135]

Tau^{vw}- transgenic for a human 4-repeat tau isoform with 2 N-terminal exons carrying the FTDP-17 mutations G272V, P301L and R406W; PDAPP - overexpressing the human amyloid precursor protein containing the Indiana familial AD mutation (APP^{V717F}); JNPL3 - line overexpressing mutant human tau (P301L, 4R0N); PrP T44 Tg - overexpression of the smallest human tau isoform in the mouse CNS with the mouse prion protein (PrP) promoter; GSK-3/VLW - mice overexpressing GSK-3 and FTDP-17-tau; hAPPtg - tg mice expressing mutant human APP under the Thy1 promoter; 3xTg-AD mice - line expressing human APP^{sw} and the human tau_{P301L}; APP^{sw}-tau^{vw} overexpressing human mutant APP (Swedish mutation K670N-M671L) and a triple human tau mutation associated with frontotemporal dementia and parkinsonism linked to chromosome 17 (G272V, P301L and R406W); Tgtau30 express a mutant tau transgene (1N4R human tau isoform) mutated at positions G272V and P301S, under the control of a modified thy-1 promoter; MMBO -2-methyl-5-(3(4((S)methylsulfinyl)phenyl)-1-benzofuran-5-yl)-1,3,4-oxadiazole

APP/Tau mouse model with a specific GSK-3 inhibitor reduced tau phosphorylation and A β deposition, together with prevention of memory deficits and increase in neuronal survival [81]. Other selective inhibitors of GSK-3 α/β also suggested reduction in A β production, in particular via an increase of degradation of APP through the activation of a lysosome/autophagy pathway [77]. Based

on these promising findings, some GSK-3 inhibitors have entered into preclinical and clinical trials [82,83].

Numerous factors may affect tau phosphorylation, and many of them are also assessed for pharmacological application in AD patients. Brain-derived neurotrophic factor (BDNF), an extracellular factor that is down-regulated in AD brains, has been considered as one of the critical contributors to dementia due to its role in cognition, learning, and memory through the modulation of synaptic plasticity in adulthood [84,85]. Regarding GSK-3 β , exposure to BDNF induces a rapid decrease in tau phosphorylation at specific phosphorylation sites through a PI3-K/Akt and downstream GSK-3 β signaling transduction cascade [86]. PI3-K activates Akt/protein kinase B, while activated Akt in turn phosphorylates GSK-3 β and induces its inactivation (Figure 1). Moreover, A β at levels insufficient to cause degeneration interferes with BDNF-induced activation of PI3-K/Akt pathway [87], indicating a potential link between an increase in A β levels and hyperphosphorylation of tau protein in AD, which may be of importance for novel therapeutic approaches [86]. In contrast, accumulation of A β leads to downregulation of Akt, increase in activation of GSK-3 β , and apoptosis, while downregulation of Akt paralleled intracellular A β accumulation *in vivo* in the Tg2576 AD mouse model [88]. Interestingly, presenilin 1 also induces tau dephosphorylation and promote cell survival due to PI-3K/Akt-mediated inhibition of GSK-3 activity [89].

Spingolipids in the pathogenesis of AD

Spingolipids are a heterogeneous class of lipids derived from sphingosine, an aliphatic amino alcohol. The first, rate-limiting step in their synthesis is formation of sphingosine from palmitoyl-CoA and Ser by serine palmitoyltransferase (SPT). Beside important structural role, particularly in lipid rafts, sphingolipids and their metabolites also act as second messengers in diverse signaling pathways involved in signal transduction, cell growth and differentiation, and apoptosis [90,91]. Although sphingolipids represent only

a small proportion of the total cellular lipid pool [92], studies suggest that even subtle disturbances in their balance may be involved in the development of neurodegenerative diseases. Diverse methodological approaches have identified altered pathways and products of sphingolipid metabolism that contribute to the pathogenesis of AD, including A β pathology, tau formation, and neurodegeneration [93-95]. Hence, preservation of neuronal sphingolipid homeostasis is of major importance for normal brain functioning and potential target for novel therapeutic approaches.

The major bioactive mediators formed by sphingolipid metabolism are multiple ceramides, sphingosine, ceramide-1-phosphate, sphingosine-1-phosphate and glycosphingolipids [92,95]. Several studies indicated that ceramides and sphingosine mediate apoptosis, growth arrest, and senescence, while their phosphorylated derivatives promote proliferative and anti-apoptotic activities [92,96], although it is also observed that endogenous and exogenous ceramides could protect cortical neurons obtained from wild-type mice against A β toxicity and A β -induced increase in tau phosphorylation by inhibiting cdk5 activity [97]. Irrespective of this controversial finding, it is evident that neuronal survival could be determined with very small shifts in ceramide metabolism [98].

Spingolipids in AD

Ceramides (Cer), the major molecules of sphingolipid metabolic pathways, are expressed in both neurons and astrocytes. They are composed of sphingosine attached by an amide bond to fatty acids, varying in length from 14 to 26 carbon atoms. On this basic backbone, different moieties can be attached forming complex sphingolipids [91,99]. Hence, glycosphingolipids are formed through Cer glycosylation. Shift in sphingolipid metabolism toward accumulation of Cer and decrease of glycosphingolipids, together with the reduction of anti-apoptotic signaling, has been suggested as a function of the disease progression [100]. On human neuroblastoma SH-SY5Y cells, inhibition of glycosphingolipids biosynthesis markedly reduced secretion

of soluble APP and A β , indicating one more potential therapeutic avenue in the inhibition of A β production [101].

Sphingomyelin, one of the most abundant mammalian sphingolipid especially enriched in the myelin sheet that surrounds axons of neuronal cells, is formed when phosphorylcholine is attached to Cer. Increased levels of sphingomyelin are found in the cerebrospinal fluids of patients in prodromal AD exclusively [102], and increased sphingomyelin/Cer ratio is considered for potential use as sensitive blood-based biomarker for disease progression [103].

Sphingosine, formed in the deacylation of Cer by enzyme ceramidase, can be metabolized to sphingosine-1-phosphate and fine-tuning between concentrations of these metabolites may determine cell fate [95]. As mentioned above, effects of sphingosine-1-phosphate are considered mostly as beneficial [96], although the proteolytic activity of β -secretase may be increased in direct interaction with sphingosine-1-phosphate [104].

Gangliosides, a highly heterogeneous family of glycosphingolipids that contain sialic acid, are also concentrated in lipid rafts, and able to affect neuronal plasticity and cell survival. Composition and amount of some gangliosides change with age, and it is thought that gangliosides also contribute to AD pathology by binding to A β that further leads to the formation of large A β assemblies [105-107].

Sulfatides, sulfated galactocerebrosides synthesized almost exclusively by oligodendrocytes and present predominantly in the myelin sheath, are also a class of sphingolipids probably involved in AD pathogenesis [107]. It seems that levels of sulfatides are depleted in AD brains, particularly at the stage of very mild dementia [108]. Interestingly, it has been shown that sulfatides may function as effective stimulators for autophosphorylation of GSK-3 β [109].

Anabolic and catabolic pathways of sphingolipid metabolism: implications for AD pathology

Sphingomyelin can be hydrolyzed to Cer through the actions of ubiquitous acidic and brain-specific neutral sphingomyelinases

that are activated by oxidative stress and inflammatory processes [98]. In SH-SY5Y cells and primary cortical neurons, the proinflammatory modulator TNF- α stimulates Mg²⁺-dependent neutral sphingomyelinase activity, and elicits sphingomyelin hydrolysis and Cer increase [98]. Endogenous Cer can also be generated by a *de novo* synthesis pathway. Elevated basal level of particular species of Cer in serum is associated with a higher risk for developing AD [110]. Cer are increased approximately three times in brains from AD patients [108], particularly in vulnerable regions [111]. Besides increased levels of Cer [112], gene expression abnormalities of enzymes that participate in sphingolipid metabolism, including both sphingomyelinases, are also found at different stages of AD progression [113]. A detailed RNA analysis revealed 28 genes involved in Cer homeostasis whose expression was altered through the disease progression. In particular, gene expression of the enzymes involved in *de novo* synthesis of Cer was increased, while downregulation of the enzymes participating in glycosphingolipid synthesis occurred [100].

Because Cer exhibit neurotoxic properties acting as pro-apoptotic molecules, increased activity of sphingomyelinases promotes loss of neuronal cells [112,114,115]. The mechanism leading to cell death may involve, at least in part, a mitochondrial PP2A that dephosphorylates and inactivates the major anti-apoptotic protein Bcl-2 [116]. *In vitro* and *in vivo* studies pointed out to associations between Cer and A β . Endogenous pool of Cer strictly regulates A β biogenesis, in a way that elevated ceramide levels directly increase A β level [117]. Membrane Cer, as the major component of lipid rafts, facilitate A β production by increasing the half-life of β -secretase (BACE1) and affecting its molecular stability [117,118]. In turn, oligomeric soluble A β and fibrillar A β_{1-42} activates neutral and acidic sphingomyelinases [119,120]. Hence, A β -dependent increase in ceramide levels leads to further increase in A β production (Figure 1). In addition, upregulated sphingomyelinase correlates with increased tau hyperphosphorylation in AD brains [112]. On the other hand, activation of SPT also might increase Cer levels and contribute to AD

pathology. SPT consists of SPTLC1 and SPTLC2 subunits, and expression of both has been confirmed in senile plaques [121].

Interaction of astroglia and neurons in sphingolipid metabolism and AD pathology

SPT upregulation in astrocytes is implicated in upregulation of sphingomyelinase activity in neurons. Soluble products released from palmitic acid (PA)-activated human astroglia activates neutral sphingomyelinase and increases Cer levels and cell death in primary neuronal cultures [122]. In particular, exposure to PA, the most common saturated fatty acid, increases endogenous Cer production in astroglia, which in turn is involved in both increased amyloidogenesis and tau hyperphosphorylation in neurons exposed to conditioned media from PA-treated astrocytes [118,123]. As direct treatment of primary neurons with PA had no effect on the BACE1 activity and A β levels [124], such studies emphasized the essential role of abnormal astroglial Cer metabolism in causing pathophysiological changes characteristic of AD. PA-induced SPT activation and *de novo* synthesis of Cer in astrocytes is involved in the production of the cytokines TNF- α and IL-1 β . These soluble cytokines, after release into conditioned media activate sphingomyelinases in neurons, and through the catabolic pathway, increase Cer level and upregulate BACE1 and amyloidogenesis [123]. Increased extracellular A β could in turn act on both astroglia and neurons, and further enhance Cer levels, reinforcing a Cer-A β -Cer cascade [123]. Interestingly, the APP intracellular domain (AICD) decreases the expression of the SPTLC2, the catalytic subunit of the SPT heterodimer, decreasing the SPT activity [125]. Inhibition of SPT in an early-onset mouse model of AD by inhibitor L-cycloserine reduced cortical SPT protein levels, which in turn decreased Cer and induced downregulation of cortical A β_{1-42} , and also decreased soluble hyperphosphorylated tau level without evident toxic effects [121]. Since L-cycloserine also acts as a partial agonist of *N*-methyl-D-aspartate receptors, cognitive enhancements have been observed following its administration

in AD patients [126]. Likewise, treatment of neurons with conditioned media obtained from astroglia exposed to both free fatty acids and L-cycloserine was able to decrease levels of increased A β , hyperphosphorylated tau, and activated GSK-3 β [118]. Other studies also linked Cer to tau phosphorylation. It was shown that Cer modulate PP2A activity [127], and increase tau phosphorylation by cdk5 at specific sites [128]. Beside direct impact on A β pathology, increase in Cer stimulates free radical generation, establishing a link between sphingolipid metabolism and oxidative stress that further exacerbates neuronal degeneration [98]. Hence, therapeutic strategies based on the reduction of Cer accumulation have the potential to prevent tau phosphorylation and further studies *in vivo* are needed to clarify these approaches, particularly in combination with other targets.

Conclusions

In spite of major research efforts, effective treatments for devastating neurodegenerative disorders, such as AD, are still lacking. As AD arise from the combination of different mechanisms (Figure 1), it is generally believed that prevention or reduction of AD pathology should rely on the inhibition of various steps involved in the early stages of disease progression. Several molecular targets represent rational therapeutic approaches for improvement of AD therapy. Among them are GSK-3 β and enzymes involved in sphingolipid metabolism. GSK-3 β has been identified as a major tau kinase and a signaling link between A β and tau pathology, and reduction of its activity certainly has valuable therapeutic potential. However, due to the large number of phosphorylation sites and the many protein kinases implicated in tau pathology, it is argued that valid strategies should be directed to overall reductions in cellular level of tau phosphorylation by targeting kinases with broad inhibitors. In addition, such an approach will probably have minor adverse effects on the physiological roles of targeted enzymes and fewer problems with tolerability and toxicity that are common in elderly [1]. Another prospective avenue in AD therapy is

the modulation of sphingolipids metabolism. Drugs acting along sphingomyelinases and SPT metabolic pathways have recently attracted increasing attention. Beneficial outcomes of pharmacological studies suggest that modulation of Cer-regulated pathways, together with attenuation of kinase activity,

may represent a promising strategy to counter pathology development in AD treatment.

Acknowledgments

Supported by the Croatian Ministry of Science, Education and Sport (grant 098-0000000-

2448), the Croatian Science Foundation (grant 09/16), and the NIH (grant P50 AG005138). All authors participated in writing and the critically editing the manuscript.

References

- [1] Hanger D.P., Anderton B.H., Noble W., Tau phosphorylation: the therapeutic challenge for neurodegenerative disease, *Trends Mol. Med.*, 2009, 15, 112-119
- [2] Solfrizzi V., D'Introno A., Colacicco A.M., Capurso C., Del Parigi A., Capurso S., et al., Dietary fatty acids intake: possible role in cognitive decline and dementia, *Exp. Gerontol.*, 2005, 40, 257-270
- [3] Takechi R., Galloway S., Palbage-Gamarallage M.M., Lam V., Mamo J.C., Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk, *Prog. Lipid Res.*, 2010, 49, 159-170
- [4] Roher A.E., Weiss N., Kokjohn T.A., Kuo Y.M., Kalback W., Anthony J., et al., Increased A β peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease, *Biochemistry*, 2002, 41, 11080-11090
- [5] Presečki P., Mück-Šeler D., Mimica N., Pivac N., Mustapić M., Stipčević T., et al., Serum Lipid Levels in Patients with Alzheimer's Disease, 2011, *Coll. Antropol.*, 35, Suppl. 1, 115-120
- [6] Grundke-Iqbal I., Iqbal K., Quinlan M., Tung Y.-C., Zaidi M.S., Wisniewski H.M., Microtubule-associated protein tau. A component of Alzheimer paired helical filaments, *J. Biol. Chem.*, 1986, 6084-6089
- [7] Blennow K., de Leon M.J., Zetterberg H., Alzheimer's disease, *Lancet*, 2006, 368, 387-403
- [8] Gouras G.K., Tampellini D., Takahashi R.H., Capetillo-Zarate E., Intraneuronal β -amyloid accumulation and synapse pathology in Alzheimer's disease, *Acta Neuropathol.*, 2010, 119, 523-541
- [9] Šimić G., Gnjidić M., Kostović I., Cytoskeletal changes as an alternative view on pathogenesis of Alzheimer's disease, *Period. Biol.*, 1998, 100, 165-173
- [10] Brandt R., Hundelt M., Shahani N., Tau alteration and neuronal degeneration in tauopathies: mechanisms and models, *Biochim. Biophys. Acta*, 2005, 1739, 331-354
- [11] Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., Ferreira A., Tau is essential to β -amyloid-induced neurotoxicity, *Proc. Natl. Acad. Sci. USA*, 2002, 99, 6364-6369
- [12] Resende R., Ferreira E., Pereira C., Resende Oliveira C., ER stress is involved in A β -induced GSK-3 β activation and tau phosphorylation, *J. Neurosci. Res.*, 2008, 86, 2091-2099
- [13] Huang H.C., Jiang Z.F., Accumulated amyloid- β peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease, *J. Alzheimers Dis.*, 2009, 16, 15-27
- [14] Zhang Z., Zhao R., Qi J., Wen S., Tang Y., Wang D., Inhibition of glycogen synthase kinase-3 β by *Angelica sinensis* extract decreases β -amyloid-induced neurotoxicity and tau phosphorylation in cultured cortical neurons, *J. Neurosci. Res.*, 2011, 89, 437-447
- [15] Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J., Soluble amyloid β -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration, *Proc. Natl. Acad. Sci. USA*, 2011, 108, 5819-5824
- [16] Chabrier M.A., Blurton-Jones M., Agazaryan A.A., Nerhus J.L., Martinez-Coria H., LaFerla F.M., Soluble A β promotes wild-type tau pathology in vivo, *J. Neurosci.*, 2012, 32, 17345-17350
- [17] McKee A.C., Carreras I., Hossain L., Ryu H., Klein W.L., Oddo S., et al., Ibuprofen reduces A β , hyperphosphorylated tau and memory deficits in Alzheimer mice, *Brain Res.*, 2008, 1207, 225-236
- [18] Lanzillotta A., Sarnico I., Benarese M., Branca C., Baiguera C., Hutter-Paier B., et al., The γ -secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease, *J. Mol. Neurosci.*, 2011, 45, 22-31
- [19] Hernandez P., Lee G., Sjoberg M., Maccioni R.B., Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide A β 25-35: involvement of lipid rafts, *J. Alzheimers Dis.*, 2009, 16, 149-156
- [20] Kawarabayashi T., Shoji M., Younkin L.H., Wen-Lang L., Dickson D.W., Murakami T., et al., Dimeric amyloid β protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease, *J. Neurosci.*, 2004, 24, 15, 3801-3809
- [21] Grimm M.O.W., Rothhaar T.L., Hartmann T., The role of APP proteolytic processing in lipid metabolism, *Exp. Brain Res.*, 2012, 217, 365-375
- [22] Aronov S., Aranda G., Behar L., Ginzburg I., Visualization of translated tau protein in the axons of neuronal P19 cells and characterization of tau RNP granules, *J. Cell Sci.*, 2002, 115, 3817-3827
- [23] Esmaeli-Azad B., McCarty J.H., Feinstein S.C., Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability, *J. Cell Sci.*, 1994, 107, 869-879
- [24] Šimić G., Stanić G., Mladinov M., Jovanov-Milošević N., Kostović I., Hof P.R., Does Alzheimer's disease begin in the brainstem?, *Neuropathol. Appl. Neurobiol.*, 2009, 35, 532-554
- [25] Takuma H., Arawaka S., Mori H., Isoforms changes of tau protein during development in various species, *Dev. Brain Res.*, 2003, 142, 121-127
- [26] Deshpande A., Win K.M., Busciglio J., Tau isoform expression and regulation in human cortical neurons, *FASEB J.*, 2008, 22, 2357-2367

- [27] Jovanov-Milošević N., Petrović D., Sedmak G., Vukšić M., Hof P.R., Šimić G., Human fetal tau protein isoform: possibilities for Alzheimer's disease treatment, *Int. J. Biochem. Cell. Biol.*, 2012, 44, 1290-1294
- [28] Lee G., Neve R.L., Kosik K.S., The microtubule binding domain of tau protein, *Neuron*, 1989, 2, 1615-1624
- [29] Buée L., Bussiére T., Buée-Scherrer V., Delacourte A., Hof P.R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, *Brain Res. Rev.*, 2000, 33, 95-130
- [30] Ballatore C., Lee V.M., Trojanowski J.Q., Tau-mediated neurodegeneration in Alzheimer's disease and related disorders, *Nat. Rev. Neurosci.*, 2007, 8, 663-672
- [31] Adams S.J., DeTure M.A., McBride M., Dickson D.W., Petrucelli L., Three repeat isoforms of tau inhibit assembly of four repeat tau filaments, *PLoS One*, 2010, 5, e10810
- [32] Johnson G.V., Stoothoff W.H., Tau phosphorylation in neuronal cell function and dysfunction, *J. Cell Sci.*, 2004, 117, 5721-5729
- [33] Iqbal K., Liu F., Gong C.X., Grundke-Iqbal I., Tau in Alzheimer disease and related tauopathies, *Curr. Alzheimer Res.*, 2010, 7, 656-664
- [34] Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., et al., Proline-directed and non-proline-directed phosphorylation of PHF-tau, *J. Biol. Chem.*, 1995, 270, 823-829
- [35] Wang J.Z., Xia Y.Y., Grundke-Iqbal I., Iqbal K., Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration, *J. Alzheimers Dis.*, 2013, Suppl 1, S123-S139
- [36] Gray E.G., Paula-Barbosa M., Roher A., Alzheimer's disease: paired helical filaments and cytomembranes, *Neuropathol. Appl. Neurobiol.*, 1987, 13, 91-110
- [37] Jenkins S.M., Johnson G.V., Modulation of tau phosphorylation within its microtubule-binding domain by cellular thiols, *J. Neurochem.*, 1999, 73, 1843-1850
- [38] Cho J.-H., Johnson G.V.W., Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3 β (GSK3 β) plays a critical role in regulating tau's ability to bind and stabilize microtubules, *J. Neurochem.*, 2004, 88, 349-358
- [39] Alonso A.D., Di Clerico J., Li B., Corbo C.P., Alaniz M.E., Grundke-Iqbal I., et al., Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration, *J. Biol. Chem.*, 2010, 285, 30851-30860
- [40] Iijima-Ando K., Sekiya M., Maruko-Otake A., Ohtake Y., Suzuki E., Lu B., et al., Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1, *PLoS Genet.*, 2012, 8, e1002918
- [41] Alonso A.C., Zaidi T., Novak M., Grundke-Iqbal I., Iqbal K., Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments, *Proc. Natl. Acad. Sci. USA*, 2001, 98, 6923-6928
- [42] Kimura T., Ono T., Takamatsu J., Yamamoto H., Ikegami K., Kondo A., et al., Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments, *Dementia*, 1996, 7, 177-181
- [43] Augustinack J.C., Schneider A., Mandelkow E.-M., Hyman B.T., Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease, *Acta Neuropathol.*, 2002, 103, 26-35
- [44] Arnold S.E., Hyman B.T., Flory J., Damasio A.R., Van Hoesen G.W., The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease, *Cereb. Cortex*, 1991, 1, 103-116
- [45] Braak H., Braak E., Neuropathological staging of Alzheimer-related changes, *Acta Neuropathol.*, 1991, 82, 239-259
- [46] Šimić G., Kostović I., Winblad B., Bogdanović N., Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease, *J. Comp. Neurol.*, 1997, 379, 482-494
- [47] Šimić G., Bexheti S., Kelović Z., Kos M., Grbić K., Hof P.R., et al., Hemispheric asymmetry, modular variability and age-related changes in the human entorhinal cortex, *Neuroscience*, 2005, 130, 911-25
- [48] Braak H., Thal D.R., Ghebremedhin E., Del Tredici K., Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years, *J. Neuropathol. Exp. Neurol.*, 2011, 70, 960-969
- [49] Watanabe A., Hasegawa M., Suzuki M., Takio K., Morishima-Kawashima M., Titani K., et al., In vivo phosphorylation sites in fetal and adult rat tau, *J. Biol. Chem.*, 1993, 268, 25712-25717
- [50] Avila J., Tau phosphorylation and aggregation in Alzheimer's disease pathology, *FEBS Lett.*, 2006, 580, 2922-2927
- [51] Ferrer I., Gomez-Isla T., Puig B., Freixes M., Ribé E., Dalfó E., et al., Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies, *Curr. Alzheimer Res.*, 2005, 2, 3-18
- [52] Michel G., Mercken M., Murayama M., Noguchi K., Ishiguro K., Imahori K., et al., Characterization of tau phosphorylation in glycogen synthase kinase-3 β and cyclin dependent kinase-5 activator (p23) transfected cells, *Biochim. Biophys. Acta*, 1998, 1380, 177-182
- [53] Maccioni R.B., Otth C., Concha I.I., Muñoz J.P., The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology, *Eur. J. Biochem.*, 2001, 268, 1518-1527
- [54] Li G., Yin H., Kuret J., Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules, *J. Biol. Chem.*, 2004, 279, 15938-15945
- [55] Lebouvier T., Scales T.M., Williamson R., Noble W., Duyckaerts C., Hanger D.P. et al., The microtubule-associated protein tau is also phosphorylated on tyrosine, *J. Alzheimers Dis.*, 2009, 18, 1-9
- [56] Cai Z., Yan L.-J., Li K., Quazi S.H., Zhao B., Roles of AMP-activated protein kinase in Alzheimer's disease, *Neuromol. Med.*, 2012, 14, 1-14
- [57] Martin L., Latypova X., Wilson C.M., Magnaudeix A., Perrin M.L., Yardin C., et al., Tau protein kinases: involvement in Alzheimer's disease, *Ageing Res. Rev.*, 2013, 12, 289-309
- [58] Martin L., Magnaudeix A., Esclaire F., Yardin C., Terro F., Inhibition of glycogen synthase kinase-3 β downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A, *Brain Res.*, 2009, 1252, 66-75
- [59] Matsuo E.S., Shin R.W., Billingsley M.L., Van deVoorde A., O'Connor M., Trojanowski J.Q., et al., Biopsy-derived adult human brain tau is

- phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau, *Neuron*, 1994, 13, 989-1002
- [60] Martin L., Latypova X., Wilson C.M., Magnaudeix A., Perrin M.L., Terro F., Tau protein phosphatases in Alzheimer's disease: the leading role of PP2A, *Ageing Res Rev.*, 2013, 12, 39-49
- [61] Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C.A., Imahori K., Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 β and cyclin-dependent kinase 5, a component of TPK II, *Acta Neuropathol.*, 1996, 92, 232-241
- [62] Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., et al., Distribution of active glycogen synthase kinase 3 β (GSK-3 β) in brains staged for Alzheimer disease neurofibrillary changes, *J. Neuropathol. Exp. Neurol.*, 1999, 58, 1010-1019
- [63] Leroy K., Yilmaz Z., Brion J.P., Increased level of active GSK-3 β in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration, *Neuropathol. Appl. Neurobiol.*, 2007, 33, 43-55
- [64] Phiel C.J., Wilson C.A., Lee V.M., Klein P.S., GSK-3 α regulates production of Alzheimer's disease amyloid-beta peptides, *Nature*, 2003, 423, 435-439
- [65] Wagner U., Utton M., Gallo J.-M., Miller C.C.J., Cellular phosphorylation of tau by GSK-3 β influences tau binding to microtubules and microtubule organisation, *J. Cell Sci.*, 1996, 109, 1537-1543
- [66] Muñoz-Montaño J.R., Moreno F.J., Avila J., Diaz-Nido J., Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons, *FEBS Lett.*, 1997, 411, 183-188
- [67] Cuchillo-Ibanez I., Seereeram A., Byers H.L., Leung K.Y., Ward M.A., Anderton B.H., et al., Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin, *FASEB J.*, 2008, 22, 3186-3195
- [68] Li T., Hawkes C., Qureshi H.Y., Kar S., Paudel H.K., Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3 β , *Biochemistry*, 2006, 45, 3134-3145
- [69] Terwel D., Muyllaert D., Dewachter I., Borghgraef P., Croes S., Devijver H., et al., Amyloid activates GSK-3 β to aggravate neuronal tauopathy in bigenic mice, *Am. J. Pathol.*, 2008, 172, 786-798
- [70] Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., et al., Cdk5 is a key factor in tau aggregation and tangle formation in vivo, *Neuron*, 2003, 38, 555-565
- [71] Rankin C.A., Sun Q., Gamblin T.C., Tau phosphorylation by GSK-3 β promotes tangle-like filament morphology, *Mol. Neurodegen.*, 2007, 2, 12
- [72] Lee C.W., Lau K.F., Miller C.C., Shaw P.C., Glycogen synthase kinase-3 β -mediated tau phosphorylation in cultured cell lines, *Neuroreport*, 2003, 14, 257-260
- [73] Liu S.J., Zhang A.H., Li H.L., Wang Q., Deng H.M., Netzer W.J., et al., Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory, *J. Neurochem.*, 2003, 87, 1333-1344
- [74] Su Y., Ryder J., Li B., Wu X., Fox N., Solenberg P., et al., Lithium, a common drug for bipolar disorder treatment, regulates amyloid- β precursor protein processing, *Biochemistry*, 2004, 43, 6899-6908
- [75] Takashima A., Murayama M., Murayama O., Kohno T., Honda T., Yasutake K., et al., Presenilin 1 associates with glycogen synthase kinase-3 β and its substrate tau, *Proc. Natl. Acad. Sci. USA*, 1998, 95, 9637-9641
- [76] Metcalfe M.J., Figueiredo-Pereira M.E., Relationship between tau pathology and neuroinflammation in Alzheimer's disease, *Mt. Sinai J. Med.*, 2010, 77, 50-58
- [77] Parr C., Carzaniga R., Gentleman S.M., Van Leuven F., Walter J., Sastre M., Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid- β precursor protein, *Mol. Cell. Biol.*, 2012, 32, 4410-4418
- [78] Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., et al., Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo, *Proc. Natl. Acad. Sci. USA*, 2005, 102, 6990-6995
- [79] Zhao L., Wang F., Gui B., Hua F., Qian Y., Prophylactic lithium alleviates postoperative cognition impairment by phosphorylating hippocampal glycogen synthase kinase-3 β (Ser9) in aged rats, *Exp. Gerontol.*, 2011, 46, 1031-1036
- [80] Caccamo A., Oddo S., Tran L.X., LaFerla F.M., Lithium reduces tau phosphorylation but not A β or working memory deficits in a transgenic model with both plaques and tangles, *Am. J. Pathol.*, 2007, 170, 1669-1675
- [81] Serenó L., Coma M., Rodríguez M., Sánchez-Ferrer P., Sánchez M.B., Gich I., et al., A novel GSK-3 β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo, *Neurobiol. Dis.*, 2009, 35, 359-367
- [82] Medina M., Castro A., Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic, *Curr. Opin. Drug Disc. Dev.*, 2008, 11, 533-543
- [83] Kramer T., Schmidt B., Lo Monte F., Small-molecule inhibitors of GSK-3: structural insights and their application to Alzheimer's disease models, *Int. J. Alzheimers Dis.*, 2012, 381029
- [84] Fumagalli F., Racagni G., Riva M.A., The expanding role of BDNF: a therapeutic target for Alzheimer's disease?, *Pharmacogenomics J.*, 2006, 6, 8-15
- [85] Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Müller F.J., Loring J.F., et al., Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease, *Proc. Natl. Acad. Sci. USA*, 2009, 106, 13594-13599
- [86] Elliott E., Atlas R., Lange A., Ginzburg I., Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3Kinase signalling mechanism, *Eur. J. Pharmacol.*, 2005, 22, 1081-1089
- [87] Tong L., Balazs R., Thornton P.L., Cotman C.W., β -amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons, *J. Neurosci.*, 2004, 24, 6799-6809
- [88] Magrané J., Rosen K.M., Smith R.C., Walsh K., Gouras G.K., Querfurth H.W., Intraneuronal β -amyloid expression downregulates the Akt

- survival pathway and blunts the stress response, *J. Neurosci.*, 2005, 25, 10960-10969
- [89] Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., et al., PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations, *EMBO J.*, 2004, 23, 2586-2596
- [90] Jana A., Hogan E.L., Pahan K., Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death, *J. Neurol. Sci.*, 2009, 278, 5-15
- [91] Ben-David O., Futerman A.H., The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases, *Neuromolecular. Med.*, 2010, 12, 341-350
- [92] Rao R.P., Vaidyanathan N., Rengasamy M., Oommen A.M., Somaiya N., Jagannath M.R., Sphingolipid metabolic pathway: an overview of major roles played in human diseases, *J. Lipids*, 2013, 178910
- [93] Haughey N.J., Bandaru V.V., Bae M., Mattson M.P., Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis, *Biochim. Biophys. Acta*, 2010, 1801, 878-886
- [94] Mielke M.M., Lyketsos C.G., Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?, *Neuromol. Med.*, 2010, 12, 331-340
- [95] Mielke M.M., Haughey N.J., Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease?, *Clin. Lipidol.*, 2012, 7, 525-536
- [96] Gomez-Brouchet A., Pchejetski D., Brizuela L., Garcia V., Altié M.F., Maddelein M.L., et al., Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid- β peptide, *Mol. Pharmacol.*, 2007, 72, 341-349
- [97] Seyb K.I., Ansar S., Li G., Bean J., Michaelis M.L., Dobrowsky R.T., p35/Cyclin-dependent kinase 5 is required for protection against beta-amyloid-induced cell death but not tau phosphorylation by ceramide, *J. Mol. Neurosci.*, 2007, 31, 23-35
- [98] Barth B.M., Gustafson S.J., Kuhn T.B., Neutral sphingomyelinase activation precedes NADPH oxidase-dependent damage in neurons exposed to the proinflammatory cytokine TNF α , *J. Neurosci. Res.*, 2012, 90, 229-242
- [99] Grösch S., Schiffmann S., Geisslinger G., Chain length-specific properties of ceramides, *Prog. Lipid Res.*, 2012, 51, 50-62
- [100] Katsel P., Li C., Haroutunian V., Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?, *Neurochem. Res.*, 2007, 32, 845-856
- [101] Tamboli I.Y., Prager K., Barth E., Heneka M., Sandhoff K., Walter J., Inhibition of glycosphingolipid biosynthesis reduces secretion of the β -amyloid precursor protein and amyloid β -peptide, *J. Biol. Chem.*, 2005, 280, 28110-28117
- [102] Kosicek M., Zetterberg H., Andreasen N., Peter-Katalinic J., Hecimovic S., Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease, *Neurosci. Lett.*, 2012, 516, 302-305
- [103] Mielke M.M., Haughey N.J., Bandaru V.V., Weinberg D.D., Darby E., Zaidi N., et al., Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease, *J. Alzheimers Dis.*, 2011, 27, 259-269
- [104] Takasugi N., Sasaki T., Suzuki K., Osawa S., Isshiki H., Hori Y., et al., BACE1 activity is modulated by cell-associated sphingosine-1-phosphate, *J. Neurosci.*, 2011, 31, 6850-6857
- [105] Yanagisawa K., Odaka A., Suzuki N., Ihara Y., GM1 ganglioside-bound amyloid β -protein (A β): a possible form of preamyloid in Alzheimer's disease, *Nat. Med.*, 1995, 1, 1062-1066
- [106] Utsumi M., Yamaguchi Y., Sasakawa H., Yamamoto N., Yanagisawa K., Kato K., Up-and-down topological mode of amyloid β -peptide lying on hydrophilic/hydrophobic interface of ganglioside clusters, *Glycoconj. J.*, 2009, 26, 999-1006
- [107] Grimm M.O.W., Zimmer V.C., Lehmann J., Grimm H.S., Hartmann T., The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease, *BioMed Res. Int.*, 2013, 814390
- [108] Han X., Holtzman M.D., McKeel D.W. Jr., Kelley J., Morris J.C., Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis, *J. Neurochem.*, 2002, 82, 809-818
- [109] Kawakami F., Yamaguchi A., Suzuki K., Yamamoto T., Ohtsuki K., Biochemical characterization of phospholipids, sulfatide and heparin as potent stimulators for autophosphorylation of GSK-3 β and the GSK-3 β -mediated phosphorylation of myelin basic protein in vitro, *J. Biochem.*, 2008, 143, 359-367
- [110] Mielke M.M., Bandaru V.V., Haughey N.J., Xia J., Fried L.P., Yasar S., et al., Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II, *Neurology*, 2012, 79, 633-641
- [111] Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., et al., Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease, *Proc. Natl. Acad. Sci. USA*, 2004, 17, 2070-2075
- [112] He X., Huang Y., Li B., Gong C.X., Schuchman E.H., Deregulation of sphingolipid metabolism in Alzheimer's disease, *Neurobiol. Aging*, 2010, 31, 398-408
- [113] Filippov V., Song M.A., Zhang K., Vinters H.V., Tung S., Kirsch W.M., et al., Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases, *J. Alzheimers Dis.*, 2012, 29, 537-547
- [114] Toman R.E., Movsesyan V., Murthy S.K., Miltien S., Spiegel S., Faden A.I., Ceramide-induced cell death in primary neuronal cultures: upregulation of ceramide levels during neuronal apoptosis, *J. Neurosci. Res.*, 2002, 68, 323-330
- [115] Zhang X., Wu J., Dou Y., Xia B., Rong W., Rimbach G., et al., Asiatic acid protects primary neurons against C2-ceramide-induced apoptosis, *Eur. J. Pharmacol.*, 2012, 679, 51-59
- [116] Ruvolo P.P., Deng X., Ito T., Carr B.K., May W.S., Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A, *J. Biol. Chem.*, 1999, 274, 20296-20300
- [117] Puglielli L., Ellis B.C., Saunders A.J., Kovacs D.M., Ceramide stabilizes β -site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid β -peptide biogenesis, *J. Biol. Chem.*, 2003, 30, 19777-19783

- [118] Patil S., Melrose J., Chan C., Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons, *Eur. J. Neurosci.*, 2007, 26, 2131-2141
- [119] Jana A., Pahan K., Fibrillar amyloid- β peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease, *J. Biol. Chem.*, 2004, 279, 51451-51459
- [120] Malaplate-Armand C., Florent-Bécharde S., Youssef I., Koziel V., Sponne I., Kriem B., et al., Soluble oligomers of amyloid- β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway, *Neurobiol. Dis.*, 2006, 23, 178-189
- [121] Geekiyanage H., Upadhye A., Chan C., Inhibition of serine palmitoyltransferase reduces A β and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease, *Neurobiol. Aging*, 2013, 34, 2037-2051
- [122] Jana A., Pahan K., Fibrillar amyloid- β -activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease, *J. Neurosci.*, 2010, 30, 12676-12689
- [123] Liu L., Martin R., Chan C., Palmitate-activated astrocytes via serine palmitoyl transferase increase BACE1 in primary neurons by sphingomyelinases, *Neurobiol. Aging*, 2013, 34, 540-550
- [124] Patil S., Sheng L., Masserang A., Chan C., Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons, *Neurosci. Lett.*, 2006, 406, 55-99
- [125] Grimm M.O., Grösgen S., Rothhaar T.L., Burg V.K., Hundsdörfer B., Hauptenthal V.J., et al., Intracellular APP domain regulates serine-palmitoyl-CoA transferase expression and is affected in Alzheimer's disease, *Int. J. Alzheimers Dis.*, 2011, 695413
- [126] Tsai G.E., Falk W.E., Gunther J., Coyle J.T., Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment, *Am. J. Psychiatry*, 1999, 156, 467-469
- [127] Mukhopadhyay A., Saddoughi S.A., Song P., Sultan I., Ponnusamy S., Senkal C.E., et al., Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling, *FASEB J.*, 2009, 23, 751-763
- [128] Darios F., Muriel M.P., Khondiker M.E., Brice A., Ruberg M., Neurotoxic calcium transfer from endoplasmic reticulum to mitochondria is regulated by cyclin-dependent kinase 5-dependent phosphorylation of tau, *J. Neurosci.*, 2005, 25, 4159-4168
- [129] Pérez M., Hernández F., Lim F., Díaz-Nido J., Avila J., Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model, *J. Alzheimers Dis.*, 2003, 5, 301-308
- [130] Nakashima H., Ishihara T., Suguimoto P., Yokota O., Oshima E., Kugo A., et al., Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies, *Acta Neuropathol.*, 2005, 110, 547-556
- [131] Engel T., Goñi-Oliver P., Lucas J.J., Avila J., Hernández F., Chronic lithium administration to FTDP-17 tau and GSK-3 β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert, *J. Neurochem.*, 2006, 99, 1445-1455
- [132] Rockenstein E., Torrance M., Adame A., Mante M., Bar-on P., Rose J.B., et al., Neuroprotective effects of regulators of the glycogen synthase kinase-3 β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation, *J. Neurosci.*, 2007, 27, 1981-1991
- [133] Leroy K., Ando K., Héraud C., Yilmaz Z., Authélet M., Boeynaems J.M., et al., Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology, *J. Alzheimers Dis.*, 2010, 19, 705-719
- [134] Onishi T., Iwashita H., Uno Y., Kunitomo J., Saitoh M., Kimura E., et al., A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease, *J. Neurochem.*, 2011, 119, 1330-1340
- [135] Noh M.Y., Chun K., Kang B.Y., Kim H., Park J.S., Lee H.C., et al., Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid- β induced cell model and in a transgenic mouse model of Alzheimer's disease, *Biochem. Biophys. Res. Commun.*, 2013, 435, 274-281